The positive bladder cancer data follows closely on the heels of another regulatory achievement for the pharmaceutical giant. On February 24, the U.S. Food and Drug Administration (FDA) granted full ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...

(Reuters) -Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a foothold in the fast-growing obesity ...